Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00868608
Other study ID # 3129K7-2001
Secondary ID B19310072008-001
Status Completed
Phase Phase 2
First received March 24, 2009
Last updated October 27, 2017
Start date July 30, 2009
Est. completion date June 27, 2013

Study information

Verified date October 2017
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin (CMC-544) in subjects with indolent Non-Hodgkins lymphoma (NHL) that is refractory or has relapsed after multiple therapies including rituximab or radioimmunotherapy. The investigational drug will be given to subjects with indolent NHL by intravenous infusion at a dose of 1.8 mg/m2, every 4 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 81
Est. completion date June 27, 2013
Est. primary completion date January 10, 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects who have been previously diagnosed with CD22-positive, indolent NHL (defined as follicular, marginal zone, or small lymphocytic lymphoma) that has progressed after 2 or more prior systemic therapies.

- Previous anticancer treatment given must have contained rituximab and chemotherapy, or anti CD20 Radio Immuno Therapy. Subjects must have exhibited no response or have progressed within 6 months from the completion of the most recent rituximab or rituximab containing therapy or within 12 months of the completion of Radio Immuno Therapy.

- Measurable disease with adequate bone marrow function, renal and hepatic function

Exclusion Criteria:

- History of, or suggestive of, veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS) or history of chronic liver disease (eg, cirrhosis) or suspected alcohol abuse.

- Prior allogeneic hematopoietic stem cell transplant (HSCT).

- Clinical evidence of transformation to a more aggressive subtype of lymphoma or grade 3b follicular lymphoma.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Inotuzumab Ozogamicin (CMC-544)
Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles

Locations

Country Name City State
Belgium Universitair Ziekenhuis Gent Gent
Belgium Universitaire Ziekenhuizen UZ Gasthuisberg Leuven
Belgium Oncologisch Centrum GZA - Location St. Augustinus Wilrijk
Germany Charite Berlin-Campus Virchow-Klinikum Berlin
Germany Charite Campus Mitte Berlin
Hong Kong The Chinese University of Hong Kong, Prince of Wales Hospital Shatin, N.T.
Hungary Debreceni Egyetem Orvos-es Egeszsegtudomanyi Centrum Belgyogyaszati Intezet, Debrecen
Hungary Kaposi Mor Oktato Korhaz, Belgyogyaszati Osztaly Kaposvar
Japan EPMint Co., Ltd Aichi
Japan Nagoya Daini Red Cross Hospital Aichi
Japan National Cancer Center Hospital Chuo-ku Tokyo
Japan National Hospital Organization Kyushu Cancer Center Fukuoka
Japan National Hp. Org. Kyushu Medical Center Fukuoka
Japan Tokai University Hospital Kanagawa
Japan National Cancer Center Hospital East Kashiwa Chiba
Japan Cancer Inst. Hp. of Japanese Foundation for Cancer Research Tokyo
Korea, Republic of Samsung Medical Center Seoul Korea
Netherlands Erasmus MC Apotheek Rotterdam
Netherlands Erasmus Medisch Centrum Rotterdam
Singapore Singapore General Hospital Singapore
United States Quest Diagnostics Allentown Pennsylvania
United States University of Alabama at Birmingham Birmingham Alabama
United States University of Alabama at Birmingham Comprehensive Cancer Center Birmingham Alabama
United States University of Alabama Birmingham Birmingham Alabama
United States Carlisle Regional Medical Center Lab Carlisle Pennsylvania
United States Rush University Medical Center Chicago Illinois
United States Hackensack University Medical Center Hackensack New Jersey
United States John Theurer Cancer Center Hackensack New Jersey
United States New York Medical College Hawthorne New York
United States Penn State Milton S. Hershey medical Center Hershey Pennsylvania
United States University of Texas, MD Anderson Cancer Center Houston Texas
United States Lewistown Hospital Lewistown Pennsylvania
United States Loma Linda University Cancer Center Loma Linda California
United States Loma Linda University Cancer Center #5 Loma Linda California
United States Loma Linda University Medical Center Loma Linda California
United States Facey Medical Group Mission Hills California
United States Providence Holy Cross Mission Hills California
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Barnes-Jewish Hospital Saint Louis Missouri
United States Washington University School of Medicine Saint Louis Missouri
United States Park Nicollet Frauenshuh Cancer Center Saint Louis Park Minnesota
United States CMSA Medical Lab State College Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Pfizer UCB Pharma

Countries where clinical trial is conducted

United States,  Belgium,  Germany,  Hong Kong,  Hungary,  Japan,  Korea, Republic of,  Netherlands,  Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Indolent NHL Achieving CR or Partial Response (PR) According to International Response Criteria for NHL CR was defined as complete disappearance of all target lesions and disease-related symptoms; all nodes must have decreased to normal (less than or equal to [=]1.5 cm in their greatest transverse diameter [GTD] for nodes more than [>]1.5 cm before therapy) or =1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy. PR was defined as >50% decrease in the sum of the product diameters (SPD) of up to 6 index lesions. No increase in size of other nodes, liver or spleen. Splenic and hepatic nodules must have regressed by greater than or equal to [=]50% in the SPD or GTD (for single nodules). With exception of splenic and hepatic nodules, involvement of other organs was usually assessable and no measurable disease should be present. No progression of non-target disease or new lesions. Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Secondary Percentage of Participants With Follicular NHL Achieving CR or PR According to International Response Criteria for NHL CR was defined as complete disappearance of all target lesions and disease-related symptoms; all nodes must have decreased to normal (=1.5 cm in their greatest transverse diameter for nodes >1.5 cm before therapy) or =1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy. PR was defined as >50% decrease in the SPD of up to 6 index lesions. No increase in size of other nodes, liver or spleen. Splenic and hepatic nodules must have regressed by =50% in the SPD or greatest transverse diameter (for single nodules). With exception of splenic and hepatic nodules, involvement of other organs was usually assessable and no measurable disease should be present. No progression of non-target disease or new lesions. Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Secondary Percentage of Participants With Indolent NHL Achieving a CR According to International Response Criteria for NHL CR was defined as complete disappearance of all target lesions and disease-related symptoms; all nodes must have decreased to normal (=1.5 cm in their greatest transverse diameter for nodes >1.5 cm before therapy) or =1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy. Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Secondary Percentage of Participants With Follicular NHL Achieving a CR According to International Response Criteria for NHL CR was defined as complete disappearance of all target lesions and disease-related symptoms; all nodes must have decreased to normal (=1.5 cm in their greatest transverse diameter for nodes >1.5 cm before therapy) or =1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy. Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Secondary Duration of Response in Participants With Indolent NHL Duration of response was measured from the first date of response until the first date that the objective progression of disease (PD) or symptomatic deterioration or initiation of new anticancer therapy for the lymphoma or death from any cause is documented. Participants without an event were censored at the date of the last valid tumor assessment. A valid tumor assessment visit was defined as the tumor assessment visit with overall response of CR, PR, stable disease (SD), or PD, but not 'Not Done' or 'Unknown'. PD was defined according to the International Response Criteria for NHL: 1) New lesion or increase by =50% of previously involved sites from nadir, 2) New lesion(s) >1.5 cm (any axis); =50% increase in SPD of >1 node; or =50% increase in longest diameter of previously identified node >1 cm in short axis, 3) >50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow. Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Secondary Probability of Maintaining a Response at 6, 12 and 24 Months in Participants With Indolent NHL Duration of response was measured from the first date of response until the first date that the objective PD or symptomatic deterioration or initiation of new anticancer therapy for the lymphoma or death from any cause is documented. Participants without an event were censored at the date of the last valid tumor assessment. A valid tumor assessment visit was defined as the tumor assessment visit with overall response of CR, PR, stable disease (SD), or PD, but not 'Not Done' or 'Unknown'. PD was defined according to the International Response Criteria for NHL: 1) New lesion or increase by =50% of previously involved sites from nadir, 2) New lesion(s) >1.5 cm (any axis); =50% increase in SPD of >1 node; or =50% increase in longest diameter of previously identified node >1 cm in short axis, 3) >50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow. 6, 12 and 24 months
Secondary Duration of Response in Participants With Follicular NHL Duration of response was measured from the first date of response until the first date that the objective PD or symptomatic deterioration or initiation of new anticancer therapy for the lymphoma or death from any cause is documented. Participants without an event were censored at the date of the last valid tumor assessment. A valid tumor assessment visit was defined as the tumor assessment visit with overall response of CR, PR, stable disease (SD), or PD, but not 'Not Done' or 'Unknown'. PD was defined according to the International Response Criteria for NHL: 1) New lesion or increase by =50% of previously involved sites from nadir, 2) New lesion(s) >1.5 cm (any axis); =50% increase in SPD of >1 node; or =50% increase in longest diameter of previously identified node >1 cm in short axis, 3) >50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow. Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Secondary Probability of Maintaining a Response at 6, 12 and 24 Months in Participants With Follicular NHL Duration of response was measured from the first date of response until the first date that the objective PD or symptomatic deterioration or initiation of new anticancer therapy for the lymphoma or death from any cause is documented. Participants without an event were censored at the date of the last valid tumor assessment. A valid tumor assessment visit was defined as the tumor assessment visit with overall response of CR, PR, stable disease (SD), or PD, but not 'Not Done' or 'Unknown'. PD was defined according to the International Response Criteria for NHL: 1) New lesion or increase by =50% of previously involved sites from nadir, 2) New lesion(s) >1.5 cm (any axis); =50% increase in SPD of >1 node; or =50% increase in longest diameter of previously identified node >1 cm in short axis, 3) >50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow. 6, 12 and 24 months
Secondary Kaplan-Meier Estimate of the Progression-Free Survival (PFS) in Participants With Indolent NHL Kaplan-Meier: a rule for calculating an estimate of survival. PFS was defined as time from enrollment to death from any cause without progression, progression during and after treatment, and initiation of all new anti-cancer treatments for the lymphoma. For participants with no event, censorship occurred at the date of last valid disease assessment. PD was defined in accordance with the International Response Criteria for NHL: 1) New lesion or increase by =50% of previously involved sites from nadir, 2) New lesion(s) >1.5 cm (any axis); =50% increase in SPD of >1 node; or =50% increase in longest diameter of previously identified node >1 cm in short axis, 3) >50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow. Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Secondary Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12 and 24 Months in Participants With Indolent NHL Kaplan-Meier: a rule for calculating an estimate of survival. PFS was defined as time from enrollment to death from any cause without progression, progression during and after treatment, and initiation of all new anti-cancer treatments for the lymphoma. For participants with no event, censorship occurred at the date of last valid disease assessment. PD was defined in accordance with the International Response Criteria for NHL: 1) New lesion or increase by =50% of previously involved sites from nadir, 2) New lesion(s) >1.5 cm (any axis); =50% increase in SPD of >1 node; or =50% increase in longest diameter of previously identified node >1 cm in short axis, 3) >50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow. 6, 12 and 24 months
Secondary Kaplan-Meier Estimate of the PFS in Participants With Follicular NHL Kaplan-Meier: a rule for calculating an estimate of survival. PFS was defined as time from enrollment to progression of disease or death from any cause. Events were defined as death from any cause without progression, progression during and after treatment, and initiation of all new anti-cancer treatments for the lymphoma. For participants with no event, censorship occurred at the date of last valid disease assessment. PD was defined in accordance with the International Response Criteria for NHL: 1) New lesion or increase by =50% of previously involved sites from nadir, 2) New lesion(s) >1.5 cm (any axis); =50% increase in SPD of >1 node; or =50% increase in longest diameter of previously identified node >1 cm in short axis, 3) >50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow. Assessed for up to 2 years, including planned assessments every 8 to 12 weeks from first dose of study drug. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Secondary Kaplan-Meier Estimate of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12 and 24 Months in Participants With Follicular NHL Kaplan-Meier: a rule for calculating an estimate of survival. PFS was defined as time from enrollment to progression of disease or death from any cause. Events were defined as death from any cause without progression, progression during and after treatment, and initiation of all new anti-cancer treatments for the lymphoma. For participants with no event, censorship occurred at the date of last valid disease assessment. PD was defined in accordance with the International Response Criteria for NHL: 1) New lesion or increase by =50% of previously involved sites from nadir, 2) New lesion(s) >1.5 cm (any axis); =50% increase in SPD of >1 node; or =50% increase in longest diameter of previously identified node >1 cm in short axis, 3) >50% increase from nadir in the SPD of any previous lesions (splenic or hepatic) and 4) New or recurrent involvement in bone marrow. 6, 12 and 24 months
Secondary Kaplan-Meier Estimate of the Overall Survival (OS) in Participants With Indolent NHL Kaplan-Meier: a rule for calculating an estimate of survival. OS was defined as the time from enrollment to death from any cause. For participants without death, censorship occurred at the date of last contact. Any time up to 2 years after enrollment. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Secondary Kaplan-Meier Estimates of the Probability of Survival at 6, 12 and 24 Months in Participants With Indolent NHL Kaplan-Meier: a rule for calculating an estimate of survival. OS was defined as the time from enrollment to death from any cause. For participants without death, censorship occurred at the date of last contact. 6, 12 and 24 months
Secondary Kaplan-Meier Estimate of the OS in Participants With Follicular NHL Kaplan-Meier: a rule for calculating an estimate of survival. OS was defined as the time from enrollment to death from any cause. For participants without death, censorship occurred at the date of last contact. Any time up to 2 years after enrollment. Follow-up period may have been extended beyond 2 years due to dosing delays and allowed study visit windows.
Secondary Kaplan-Meier Esitmates of the Probability of Survival at 6, 12 and 24 Months in Participants With Follicular NHL Kaplan-Meier: a rule for calculating an estimate of survival. OS was defined as the time from enrollment to death from any cause. For participants without death, censorship occurred at the date of last contact. 6, 12 and 24 months
Secondary Median Induced Change From Baseline of QT Study Specific Correction (QTcS) by Cycle Based on Median Maximum Calicheamicin Concentration (Cmax) Triplicate 12-lead electrocardiogram (ECG) measurements were performed approximately 2 minutes apart. ECG assessments were pre-specified in the protocol to be time-matched with selected pharmacokinetic (PK) samples in order to conduct a concentration-QTc analysis. A study-specific QT correction factor was estimated using the un-averaged triplicate data and was used to calculate the study-specific corrected QT (QTcS). QTcS interval versus serum concentrations were modeled using a population analysis approach to identify potential effects of total calicheamicin exposure. Results for drug effects were based on the median Cmax for total calicheamicin across all participants: median Cmax was 61.3 ng/mL Cycle 1: pre-dose, 1 hour; Cycle 3 & 4: pre-dose, 1, 3, 48, 168 hours; Cycle 6 (if applicable): pre-dose; end of treatment: during clinic visit
Secondary Percentage of Participants With a Treatment Emergent Adverse Event (TEAE) (Safety Population) Includes all TEAEs: any event that emerged after the first dose of the study treatment during the treatment period that was absent before administration of any study treatment, or worsened during the treatment period relative to the pre-treatment state. Protocol reporting period: from informed consent to at least 28 days after the last dose.
Secondary Percentage of Participants With QTc Interval Corrected Using Fridericia's Formula (QTcF) by Category (Safety Population) Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to the beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Maximum QTcF was categorized as less than or equal to (=) 450 msec, >450 msec to =480 msec, >480 msec to =500 msec and >500 msec. Participants are reported only once under the maximum QTcF interval observed at any of the time-points. Maximum increase from baseline was categorized as <30 msec, =30 to <60 msec (borderline) and =60 msec (prolonged) were summarized. Screening; Cycle 1: pre-dose & 1 hour; Cycles 3 and 4: pre-dose, 1, 3, 48, and 168 hours; Cycle 6: pre-dose; end of treatment: 28 to 56 days post-last dose.
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1